The DNA Genotek Helping Hands Program is designed to assist organizations that are innovators in disease research, disease prevention and treatment. The goal of the program is to help accelerate research and to advance the fight against disease across the globe.
DNA Genotek's Sample Collection Blog
Everyone at DNA Genotek is familiar with event-based collections. We’ve worked with dozens of customers over the years to help facilitate collecting samples for breast cancer, epilepsy, HLA-typing and more. Recently, our products were used in an event-based collection to support education and provide information on how genes are linked to our ancestry. The New Horizons Festival (NHF) was held at Erasmus MC and several other public locations in Rotterdam, the Netherlands on September 26, 2014 and over 1,500 people participated. The purpose of the event was to make science accessible and attractive to the general public by merging science with art and music to create a fun, interactive event.
Dr. Gerardo Jimenez Sanchez is a fundamental and prominent figure in the development and expansion of human genomics in Mexico. His accomplishments are equally impressive as they are extensive:
Since the launch of The Genetic Link blog back in 2009, we’ve shared dozens of stories from the field highlighting remote DNA collections, innovative approaches to research, and unique event-based collections. Each of these stories was based on a research team searching for the gene or genes responsible for a particular disease or health condition. The story in this article is unique in that it highlights a project that is hoping to attract individuals who are willing to share their personal genome, health information and trait data for a broader application. The goal is to advance scientific progress by inviting willing participants to share their personal genetic data for the greater good.
The author of this article, Lisa Gamwell, is a Sales Development Analyst at DNA Genotek.
Dr. Janet Coller, Lecturer at the University of Adelaide, has an established track record in Pharmacology and Pharmacogenetic medical research within the health areas of cancer, drug dependence, cardiology and solid-organ transplantation. Her research includes work to identify how genetic variability impacts the therapeutic use of tamoxifen for breast cancer, identifying important genetic variants that determine successful treatment of opioid dependence with methadone, and research in the emerging field of immunogenetics.
Mike Tayeb is the Technical Support Manager at DNA Genotek Inc.
Through their participation in the IMPACT research study (Individualized Medicine: Pharmacogenetic Assessment & Clinical Treatment), practitioners in Canada are now able to offer certain patients a saliva-based genetic test to predict which psychiatric medications work best for them. The tests enable physicians to use a patient’s genetic makeup to help predict which medications are safe to prescribe, and which ones may be ineffective or cause side effects. The tests are aimed at minimizing trial-and-error prescribing/dosing and are expected to reduce associated health care costs. The pharmacogenetic tests, currently offered to Centre for Addiction and Mental Health (CAMH) clients and registered patients at the Thornhill Medical Centre, use DNA from saliva collected with Oragene for the purposes of the research. Plans are being made to incorporate several other Ontario healthcare facilities into the IMPACT study. This study is making the promise of personalized medicine a reality.
Approximately 30 years ago, the Tissue Typing Laboratory at the Sheba Medical Center in Israel was created to serve a newly launched cadaver-kidney organ sharing program. The mandate of the Sheba Medical Center has evolved over the years from organ donation to include HLA typing for bone marrow transplants. The medical center performs approximately 140 pediatric and adult bone marrow transplants per year. Dr. Ephraim Gazit and his team are responsible for HLA typing in the laboratory for a variety of purposes including: HLA disease studies, to identify potential bone marrow donors in families and in the general population, to build a bone marrow registry and for organ transplantation.